5-Fluorouracil (5-Fu) commonly use in the treatment of different kinds of cancer, but limited cellular uptake and death is still a problem. Herein, we report a simple process for the synthesis of pressure-sensitive nanogels that indicate to be appropriate in the delivery of 5-Fu. The hydrogels (Al-CD) prepare by crosslinking of alginate (Al) with modified beta Cyclodextrin (β-CD) as Crosslinker. Next, nanoparticles obtaine by an emulsification method. 5-Fu as model drug loades into the Al-CD nanogels easily by mixing it in aqueous solution with the nanoparticles. The results revealed that the Al-CD nanogels are cytocompatible. They have also a noticeable drug encapsulation (82.1 ±5.7%) while they can release (in vitro controlled) 5-Fu in conditions that imitate the intravascular pressure conditions. These nanogels can rapidly be taken up by HT-29 cells (a colon cell line). In addition, a higher 5-Fu intracellular accumulation and a significant cell death extension by apoptosis mechanism is notice when compare with free 5-Fu. Accordingly, the developed nanogels can be employe as an excellent candidate to overcome the inefficiency of 5-Fu in anticancer treatments and possibly can employe for further evaluation as a chemotherapical agent in applications beyond cancer. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 349-359, 2018.

A new fluoro-bridged rare-earth (RE) metal−organic framework consisting of 15-connected nonanuclear and 9-connected trinuclear clusters {[RE 9 -(μ 3 -F) 14 (H 2 O) 6 ][RE 3 (μ 3 -F)(H 2 O) 3 ](HCO 2 ) 3 -(BTB) 6 }•(solvent)x 2 (RE = Ho 3+ and Gd 3+ ) was synthesized through the transformation of a dimeric complex formulated as bis(2,2′-bipyridine)tetrakis(μ-2-fluorobenzoato-O,O′)-bis(2fluorobenzoato)diRE(III) 1 with the bridging linker 1,3,5-tris(4-carboxyphenyl)benzene (H 3 BTB). The rare-earth metal ions Ho 3+ and Gd 3+ were also found to remove fluorine from other organo-fluorine compounds such as perfluorohexanoic acid (PFHxA) and perfluorooctanoic acid (PFOA), resulting in the new fluorobridged RE-MOFs.

A combination of a molecular imprinting technique and precipitation polymerization was applied to develop novel azithromycin-imprinted poly(methacrylic acid-co-ethylene glycol dimethacrylate) nanoparticles for sustained release of azithromycin (AZM).